These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 30455075

  • 1. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial.
    Weiser M, Levi L, Burshtein S, Chiriță R, Cirjaliu D, Gonen I, Yolken R, Davidson M, Zamora D, Davis JM.
    Schizophr Res; 2019 Apr; 206():325-332. PubMed ID: 30455075
    [Abstract] [Full Text] [Related]

  • 2. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
    Ghanizadeh A, Dehbozorgi S, OmraniSigaroodi M, Rezaei Z.
    Recent Pat Inflamm Allergy Drug Discov; 2014 Apr; 8(3):211-5. PubMed ID: 25353174
    [Abstract] [Full Text] [Related]

  • 3. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M, Akhondzadeh S.
    Psychiatry Res; 2014 Mar 30; 215(3):540-6. PubMed ID: 24480077
    [Abstract] [Full Text] [Related]

  • 4. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, Yang J, Ruan Y, Zeng Y, Xu X, Zhao J.
    Schizophr Res; 2014 Mar 30; 153(1-3):169-76. PubMed ID: 24503176
    [Abstract] [Full Text] [Related]

  • 5. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, Micluția I, Tiugan A, Păcală B, Grecu IG, Noy A, Zamora D, Davis JM.
    J Clin Psychiatry; 2017 Jul 30; 78(7):e758-e765. PubMed ID: 28541645
    [Abstract] [Full Text] [Related]

  • 6. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M, Davis SR.
    JAMA Psychiatry; 2016 Sep 01; 73(9):947-54. PubMed ID: 27438995
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.
    J Clin Psychiatry; 2002 Sep 01; 63(9):763-71. PubMed ID: 12363115
    [Abstract] [Full Text] [Related]

  • 8. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.
    J Clin Psychiatry; 2013 Dec 01; 74(12):1224-32. PubMed ID: 24434091
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 01; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 10. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment.
    Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G, Deakin B.
    J Psychopharmacol; 2012 Sep 01; 26(9):1185-93. PubMed ID: 22526685
    [Abstract] [Full Text] [Related]

  • 11. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder.
    Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L.
    Schizophr Res; 2017 Nov 01; 189():126-133. PubMed ID: 28215471
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ.
    J Clin Psychiatry; 2004 Dec 01; 65(12):1624-33. PubMed ID: 15641867
    [Abstract] [Full Text] [Related]

  • 13. Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia.
    Liu F, Zhang B, Xie L, Ruan Y, Xu X, Zeng Y, Messina L, Zhao J, Fan X.
    Schizophr Res; 2018 Sep 01; 199():390-394. PubMed ID: 29526457
    [Abstract] [Full Text] [Related]

  • 14. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.
    J Clin Psychiatry; 2012 Jun 01; 73(6):e728-34. PubMed ID: 22795211
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.
    Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S.
    J Clin Psychiatry; 2010 Feb 01; 71(2):138-49. PubMed ID: 19895780
    [Abstract] [Full Text] [Related]

  • 16. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.
    Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM, Buchanan RW.
    J Clin Psychopharmacol; 2015 Aug 01; 35(4):374-81. PubMed ID: 26082974
    [Abstract] [Full Text] [Related]

  • 17. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels.
    Zhang L, Zheng H, Wu R, Zhu F, Kosten TR, Zhang XY, Zhao J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul 13; 85():69-76. PubMed ID: 29678772
    [Abstract] [Full Text] [Related]

  • 18. Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial.
    Levi L, Zamora D, Nastas I, Gonen I, Radu P, Matei V, Ciobanu AM, Nacu A, Boronin L, Karakrah L, Davidson M, Davis JM, Weiser M.
    J Clin Psychiatry; 2022 Aug 01; 83(5):. PubMed ID: 35921506
    [Abstract] [Full Text] [Related]

  • 19. Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.
    Pandina G, Bilder R, Turkoz I, Alphs L.
    Schizophr Res; 2013 Feb 01; 143(2-3):312-8. PubMed ID: 23276482
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, Reilly J, Schaffhauser JY, Rabinowitz J, Weiser M, Luthringer R.
    Am J Psychiatry; 2017 Dec 01; 174(12):1195-1202. PubMed ID: 28750582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.